Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Parnes

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Urology|June 14, 2008
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsyIan M Thompson, Catherine M Tangen, Donna P Ankerst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical OpinionEthan Basch, Thomas K Oliver, Andrew Vickers, et al.
Cancer|May 9, 2019
Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialPaul F Pinsky, Amanda Black, Sarah E Daugherty, et al.
Cancer|May 19, 2012
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activityClara Curiel-Lewandrowski, Susan M Swetter, Janine G Einspahr, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 25, 2010
Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention TrialAshraful Hoque, Christine B Ambrosone, Cathee Till, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Canadian Consensus Conference: The FDA decision on the use of 5ARIsLaurence Klotz, Michael Chetner, Joseph Chin, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomyJason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Cancer Investigation|February 25, 2009
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agentsJeanny B Aragon-Ching, Yang-Min Ning, Clara C Chen, et al.
The Lancet. Oncology|May 9, 2014
Addressing overdiagnosis and overtreatment in cancer: a prescription for changeLaura J Esserman, Ian M Thompson, Brian Reid, et al.
BJU International|April 18, 2007
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancerWilliam D Figg, Haiqing Li, Tristan Sissung, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Urology|June 14, 2008
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsyIan M Thompson, Catherine M Tangen, Donna P Ankerst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical OpinionEthan Basch, Thomas K Oliver, Andrew Vickers, et al.
Cancer|May 9, 2019
Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialPaul F Pinsky, Amanda Black, Sarah E Daugherty, et al.
Cancer|May 19, 2012
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activityClara Curiel-Lewandrowski, Susan M Swetter, Janine G Einspahr, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 25, 2010
Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention TrialAshraful Hoque, Christine B Ambrosone, Cathee Till, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Canadian Consensus Conference: The FDA decision on the use of 5ARIsLaurence Klotz, Michael Chetner, Joseph Chin, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomyJason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Cancer Investigation|February 25, 2009
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agentsJeanny B Aragon-Ching, Yang-Min Ning, Clara C Chen, et al.
The Lancet. Oncology|May 9, 2014
Addressing overdiagnosis and overtreatment in cancer: a prescription for changeLaura J Esserman, Ian M Thompson, Brian Reid, et al.
BJU International|April 18, 2007
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancerWilliam D Figg, Haiqing Li, Tristan Sissung, et al.
Pageof 4